Buffalo NY 非小细胞肺癌临床试验
19项针对 非小细胞肺癌的研究正在 Buffalo及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
招募中3 期
- Roswell Park Cancer Institute, Buffalo
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- Roswell Park Cancer Institute, Buffalo
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
招募中3 期
- Roswell Park Cancer Institute ( Site 0184), Buffalo
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
招募中2 期
- Roswell Park Cancer Institute IDS, Buffalo
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
招募中3 期
- Roswell Park Cancer Institute, Buffalo
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
招募中3 期
- Research Site, Buffalo
Intratumoral N17350 in Advanced Solid Tumors
招募中1/2 期
- Roswell Park Comprehensive Cancer Center, Buffalo
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
招募中2 期
- Research Site, Buffalo
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
招募中3 期
- Research Site, Buffalo
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
招募中1 期
- Roswell Park Cancer Institute, Buffalo
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
招募中1 期
- Roswell Park Comprehensive Cancer Center, Buffalo
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
招募中1 期
- Roswell Park Comprehensive Cancer Center, Buffalo
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
招募中2 期
- Roswell Park Cancer Institute, Buffalo
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
招募中1 期
- Roswell Park Comprehensive Care Center, Buffalo
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
招募中1 期
- Roswell Park Cancer Institute, Buffalo
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
招募中1 期
- Roswell Cancer Institute, Buffalo
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Buffalo
Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer
招募中
- Roswell Park Cancer Institute, Buffalo
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
招募中1/2 期
- Roswell Park Cancer Institute, Buffalo
其他城市的 非小细胞肺癌试验
- Houston, TX145 项研究
- New York City, NY121 项研究
- Arlington, VA104 项研究
- Nashville, TN97 项研究
- Boston, MA90 项研究
- Los Angeles, CA87 项研究
- St. Louis, MO73 项研究
- Chicago, IL61 项研究
- Baltimore, MD60 项研究
- San Antonio, TX59 项研究
- Columbus, OH57 项研究
- Washington, DC55 项研究
Buffalo的其他研究
- 癌症（所有类型）19 项研究
- 急性髓系白血病19 项研究
- 肺癌16 项研究
- 乳腺癌16 项研究
- 卵巢癌13 项研究
- 转移性癌症11 项研究
- 前列腺癌11 项研究
- 黑色素瘤10 项研究
- 多发性骨髓瘤10 项研究
- 肥胖症9 项研究
- 伯基特淋巴瘤8 项研究
- 骨髓增生异常综合征8 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。